Article

iCARE USA receives FDA approval for latest EIDON fundus imaging system

iCare USA’s EIDON Ultra-Widefield Lens module has received FDA 510 (k) approval for distribution across the United States, the company announced Wednesday.

iCARE USA receives FDA approval for latest EIDON fundus imaging system

Source: iCare USA

iCare USA’s EIDON Ultra-Widefield Lens module has received FDA 510 (k) approval for distribution across the United States, the company announced Wednesday.

The latest addition to iCare USA’s EIDON family of retinal imaging modalities, the Ultra-Widefield lens captures 120˚ images of the retina in a single shot, or up to 200˚ with an expanded ‘mosaic’ function.

A sharp and high image quality allows for the detection of smaller details and pathology signs from the center to the periphery.

The module can be retrofitted to the majority of the EIDON fundus imaging systems enabling the acquisition of Ultra-Widefield infrared, autofluorescence, and fluorescein angiography images with an up to 200˚ panoramic view, according to a news release.

The iCare EIDON platform set new standards in retinal imaging as the first TrueColor Confocal system to combine the best features of scanning laser ophthalmoscopy (SLO) with those of standard fundus imaging, the company stated.

This technology can be applied to the Ultra-Widefield imaging, expanding the EIDON platform’s image quality to an increased field of view on the retina.

Compared to a standard field lens —which only covers a small portion of the retina and can overlook early signs of retinal pathologies — the Ultra-Widefield lens view enables EIDON diagnostics to reveal the condition of the periphery of the retina.

According to the company, image sharpness, better optical resolution, higher details, an easy-to-use interface, and patient-frendly features are designed to assist clinicians in delivering efficient care to patients.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.